Netazepide, a Gastrin/CCK2 Receptor Antagonist, Can Eradicate Gastric Neuroendocrine Tumours in Patients with Autoimmune Chronic Atrophic Gastritis Abstract #1339

Introduction: In a two-centre, 12-week, open trial in 16 patients with chronic atrophic gastritis, hypergastrinaemia, multiple gastric NETs, and raised circulating CgA, the gastrin/CCK2 receptor antagonist, netazepide, reduced the tumour number and size, and normalised CgA.
Aim(s): To treat those patients with netazepide for longer, and to identify new biomarkers.
Materials and methods: After mean 14 months off netazepide, 13 patients took it for another 52 weeks. Assessments: gastroscopy; gene transcript expression in corpus biopsies and gastrin-treated CCK2R expressing gastric epithelial (AGSGR) cells in vitro using microarrays and qPCR; and blood CgA and gastrin (p<0.01).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Malcolm Boyce
Keywords: Netazepide

To read results and conclusion, please login ...

Further abstracts you may be interested in

#200 Genome-Wide MicroRNA Expression in Small Intestine Neuroendocrine Tumors (“Midgut carcinoids”): Upregulation of miRNA-182, miRNA-183 and Downregulation of miRNA-215
Introduction: MicroRNAs (miRs) may regulate cell proliferation, differentiation, apoptosis and function as tumor suppressors or oncogenes. MiR expression is not characterized in neuroendocrine midgut carcinoids.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: PhD student Su-Chen Li
#355 MicroRNA Signatures as Novel Biomarkers in Small Intestine Neuroendocrine Tumors
Introduction: Small intestine (SI) neuroendocrine tumors (NET) arise from serotonin-producing intraepithelial cells in the SI referred to as enterochromafin cells. The detection of SI-NETs is often concomitant with the appearance of hepatic metastasis thus most patients with SI-NET have metastases at initial presentation. MicroRNAs (miRs) are post-transcriptional key regulators in tumorigenesis which regulate expression of other genes. Little evidence of miR expression or deregulation in SI-NETs has been reported.
Conference:
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Ahmed E, Martijn C, Lloyd R, ...
#406 YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids
Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Reidar Fossmark
#424 Role of MicroRNAs in Small Intestine Neuroendocrine Tumors
Introduction: Small intestinal neuroendocrine tumors (SI-NETs) arise from enterochromaffin cells, which belong to the endocrine system. MicroRNAs (miRs) are post-transcriptional regulators. They control multiple biological processes often functioning either as tumor suppressor genes or oncogenes.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Martijn C, Essaghir A, Lloyd R, ...
#427 Gastric Carcinoids: Prevalence in Europe and USA, and Rationale for Treatment with YF476, a Gastrin Receptor Antagonist
Introduction: Gastric carcinoids (GC) are tumors arising from enterochromaffin-like (ECL) cells in the gastric mucosa. Most are caused by hypergastrinaemia, which stimulates ECL-cell growth. YF476 is a potent, selective and orally active gastrin receptor antagonist in humans in vitro and in vivo. YF476 prevented and caused shrinkage of GC in animal models of the condition.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Malcolm Boyce
Authors: Boyce M, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.